- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00496379
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
12. marts 2013 opdateret af: Nancy Lin, MD
A Phase 2 Study of ZK219477 (ZK-EPO) in Patients With Breast Cancer and Brain Metastases
The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer.
ZK219477 is a chemotherapy drug that is thought to work by interfering with the ability of cancer cells to grow and divide.
It is a part of a group of drugs called "epothilones" which appear to cause shrinkage of cancer in some patients with breast cancer.
It is generally difficult for chemotherapy to enter the brain.
However, it is believed that ZK219477 crosses into the brain.
We are also studying whether an investigational MRI scan procedure may eventually help to predict which patients will benefit from ZK219477.
Studieoversigt
Detaljeret beskrivelse
- Participants will be given ZK219477 intravenously over approximately 30 minutes every three weeks.
- During all treatment cycles a physical exam and questions about the participants general health and specific questions about any problems they may be having will be performed.
- At least every three weeks blood tests will be done to assess the effect of ZK219477 on the body.
- After every 2 cycles of treatment, participants will have additional scans to assess the effect of ZK219477 on their cancer. This will include a CT scan of the abdomen, chest, and pelvis, and an MRI of the brain.
- At the time of the standard MRI, participants will be asked to undergo an additional MRI sequence, which means they will be in the MRI machine for approximately 15-20 more minutes.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
15
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Dana-Farber Cancer Institute
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Kvinde
Beskrivelse
Inclusion Criteria:
- Patients must have histologically or cytologically invasive breast cancer, with metastatic disease at the time of screening
- Measurable Central Nervous System (CNS) disease, as defined as at least one lesion > or equal too 10mm in longest dimension
- New or progressive CNS lesions after at least one prior standard CNS-directed therapy for treatment of brain metastases, which could include surgical resection, whole brain radiotherapy (WBRT), and/or stereotactic radiosurgery (SRS). Patients must have received prior WBRT, SRS or both.
- Patient has been evaluated by a radiation oncologist, who feels that the plan to evaluate systemic chemotherapy in place of additional brain radiotherapy is an acceptable option
- No increase in corticosteroid use in the week prior to study entry
- Any number prior lines of chemotherapy for metastatic breast cancer
- 18 years of age of older
- Life expectancy of greater than 12 weeks
- ECOG Performance Status 0-2
- Patients must have normal organ function as outlined in the protocol
Exclusion Criteria:
- Patients who have had chemotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier
- Patients who have had XRT within 3 weeks prior to entering the study or those who have not recovered from adverse events due to XRT
- Patients may not be receiving any other investigational agent
- Patients may not be receiving any cancer-directed therapy
- Prior treatment with investigational chemotherapy for brain metastases
- Prior treatment with epothilone for metastatic breast cancer
- Leptomeningeal carcinomatosis as the only site of CNS involvement.
- Concurrent treatment with an enzyme inducing antiepileptic drug, including phenytoin, carbamezepine, phenobarbital, or oxacarbazepine
- More than 2 seizures over the last four weeks prior to study entry
- Known contraindication to MRI or gadolinium contrast, such as cardiac pacemaker, ocular foreign body, or shrapnel
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant or breastfeeding women.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: ZK219477
|
Given intravenously over approximately 30 minutes once every 3 weeks
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate in the Central Nervous System (CNS)
Tidsramme: 2 years
|
Objective response rate is defined as at least a 50 percent reduction in the Central Nervous system target lesion volume compared to the lesion volume at baseline.
|
2 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Subjects With Adverse Events (Any Grade)
Tidsramme: 2 years
|
Adverse events per NCI CTCAE
|
2 years
|
|
Objective Response Rate in Non-Central Nervous System (CNS) Sites
Tidsramme: 2 years
|
Non-CNS response rate (according to RECIST 1.0) limited to patients with measurable non-CNS disease
|
2 years
|
|
Time to Progression at Any Site.
Tidsramme: 2 years
|
Time from date of registration until the date of the first documentation of progression or date of death (from any cause),whichever came first, up to 2 years from registration.
Progression is defined as either progression in the Central Nervous system (CNS) according to volumetric measurement (Freedman et al. 2011) and /or progression in non-Central Nervous System lesion Measured by RECIST 1.0
|
2 years
|
|
Clinical Benefit Rate.
Tidsramme: 2 years
|
CBR = CR + PR + SD > 24 weeks in CNS with at least stable non-CNS disease
|
2 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juli 2007
Primær færdiggørelse (Faktiske)
1. oktober 2009
Studieafslutning (Faktiske)
1. januar 2012
Datoer for studieregistrering
Først indsendt
3. juli 2007
Først indsendt, der opfyldte QC-kriterier
3. juli 2007
Først opslået (Skøn)
4. juli 2007
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
14. marts 2013
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
12. marts 2013
Sidst verificeret
1. marts 2013
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Hjernesygdomme
- Sygdomme i nervesystemet
- Hudsygdomme
- Neoplasmer
- Neoplasmer efter sted
- Brystsygdomme
- Neoplastiske processer
- Neoplasmer i centralnervesystemet
- Neoplasmer i nervesystemet
- Brystneoplasmer
- Neoplasma Metastase
- Neoplasmer i hjernen
- Sygdomme i centralnervesystemet
- Molekylære mekanismer for farmakologisk virkning
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitose modulatorer
- Epothilones
- Sagopilone
Andre undersøgelses-id-numre
- 06-268
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .